Case Study
Rescuing a Stalled Asset Limited by Variability and Instability
A clinically promising molecule faced programme delays due to inconsistent exposure and formulation instability. We redesigned the development strategy to restore viability and enable progression.
The Challenge
The molecule had demonstrated early signs of clinical potential but failed to progress due to inconsistent pharmacokinetic performance and formulation limitations.
Key issues included:
- High inter- and intra-subject variability in exposure
- Instability under physiological and storage conditions
- Sensitivity to formulation and manufacturing conditions
- Poor reproducibility across batches
These challenges resulted in:
- Unreliable clinical data
- Difficulty in dose optimisation
- Increased risk of programme discontinuation
Understanding the Underlying Complexity
The variability was not attributable to a single factor but arose from a combination of:
- Solubility-limited absorption
- Formulation-dependent precipitation
- Instability in gastrointestinal conditions
- Process-induced variability during manufacturing
This required a multi-dimensional solution, rather than incremental optimisation.
Our Approach
We implemented an integrated strategy combining formulation engineering, mechanistic understanding, and process alignment to stabilise performance and reduce variability.
Root Cause Mapping
Systematic evaluation of physicochemical and biopharmaceutical properties. Identification of instability triggers and variability drivers.
Predictive Assessment
Use of modelling and experimental data to understand absorption behaviour. Evaluation of formulation–performance relationships.
Formulation Redesign
Development of a stabilised delivery system. Optimisation for solubilisation, precipitation control, and consistency.
Process Alignment
Refinement of manufacturing parameters to ensure batch-to-batch reproducibility.
Iterative Validation
Alignment of in vitro, preclinical, and early clinical signals. Continuous optimisation based on performance feedback.
Solution Implemented
A redesigned formulation system was developed to improve stability and control drug release and absorption dynamics.
This included:
- Stabilisation of the drug in gastrointestinal conditions
- Reduction of precipitation risk
- Improved robustness to manufacturing variability
The approach ensured that performance was not only improved — but also reproducible and scalable.
Outcomes
Significant reduction in PK variability across subjects
Improved exposure consistency
Enhanced formulation stability under relevant conditions
Restored confidence in dose–response relationship
Enabled continuation of clinical development
What Made the Difference
Integrated understanding of formulation, PK, and process interactions
Focus on variability reduction — not just mean exposure improvement
Alignment between formulation design and manufacturing robustness
Data-driven, iterative optimisation across development stages
Strategic Impact
Prevented potential programme discontinuation
Reduced risk in ongoing and future clinical studies
Improved confidence in regulatory and clinical strategy
Enabled a scalable path towards commercialisation
Where This Approach Applies
Process Snapshot
Root cause analysis
Predictive assessment
Formulation redesign
Process optimisation
Validation & scale readiness
Details have been generalised to preserve confidentiality whilst accurately representing the scientific and development approach.
Facing variability or instability challenges?
We help rescue and stabilise complex molecular assets through integrated, data-driven development strategies.
Evaluate your molecule